Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial

Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial

A trivalent high-dose inactivated influenza vaccine has been licensed in healthy adults ≥65 years of age and provides better protection against influenza infection and related complications than trivalent standard-dose vaccine. This phase I/II clinical trial (NCT03233217), conducted at two sites in...

Full description

Bibliographic Details
Main Authors: Leilani Sanchez, Osamu Matsuoka, Satoshi Inoue, Takahiro Inoue, Ya Meng, Takahiro Nakama, Kumiko Kato, Aseem Pandey, Lee-Jah Chang
Format: Article
Language:English
Published: Taylor & Francis Group 2020-04-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
quadrivalent influenza vaccine
high-dose influenza vaccine
elderly adults
immunogenicity
safety
japan
intramuscular
subcutaneous
Online Access:http://dx.doi.org/10.1080/21645515.2019.1677437

Internet

http://dx.doi.org/10.1080/21645515.2019.1677437

Similar Items